...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Taxotere Induces Dephosphorylation of MET in Patient-derived Tumor Models
【24h】

Taxotere Induces Dephosphorylation of MET in Patient-derived Tumor Models

机译：纳税人在患者衍生的肿瘤模型中诱导遇见的次磷酸化

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: Although molecular targeting therapy is an attractive treatment for cancer, resistance eventually develops in most cases. Here, we evaluated chemotherapeutic efficacy on non-small cell lung cancer (NSCLC) with acquired resistance to epidermal growth factor receptor inhibitors mechanistically. Materials and Methods: Antitumor effects of taxotere were evaluated using multiple models, including xenograft, and patient-derived models developed from adenocarcinoma cancer patients. Protein expressions were analyzed after drug treatment. Results: Taxotere inhibited tumor growth of NSCLC cells harboring drug resistance, and reduced the expression of phosphorylated MET proto-oncogene, receptor tyrosine kinase (MET). A tumor-inhibitory effect of taxotere was also demonstrated in vivo in xenografts in mice, patient-derived primary lung tumor cells and patient-derived xenograft with concomitant repression of phosphorylated MET expression. Chemotherapeutic and MET-targeting drug exhibited a synergistic cell growthinhibitory effect. Conclusion: These results suggest that the anticancer drug taxane may be an adjuvant for lung tumors exhibiting enhanced signaling of MET networks.
机译：背景/目的：虽然分子靶向治疗是对癌症的有吸引力的治疗，但在大多数情况下，抗性最终发生。在这里，我们对非小细胞肺癌（NSCLC）的化疗疗效进行了机械地与表皮生长因子受体抑制剂的获得性。材料和方法：使用多种模型，包括异种移植物和从腺癌癌症患者开发的患者衍生模型进行评估的抗肿瘤效应。药物治疗后分析蛋白质表达。结果：Taxotere抑制了患有耐药性的NSCLC细胞的肿瘤生长，并降低了磷酸化的Met原癌基因，受体酪氨酸激酶（Met）的表达。还在小鼠的卵黄移植物中的体内肿瘤抑制效果在小鼠，患者衍生的原发性肺肿瘤细胞和患者衍生的异种移植物中展示，具有伴随抑制磷酸化的Met表达。化学治疗和符合靶向药物表现出协同细胞生长效应。结论：这些结果表明，抗癌毒品紫杉烷可能是肺肿瘤的佐剂，其肿瘤表现出增强的MET网络信号。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号